Catalyst

Slingshot members are tracking this event:

Allergran (AGN) and Paratek (PRTK) set to file NDA for Sarecycline, an antibiotic designed to treat inflammatory acne, in 2H 2017

Source Link:
https://www.allergan.com/News/News/Thomson-Reuters/Allergan-and-Paratek-Announce-Positive-Results-Fro

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AGN Community voting in process
PRTK Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Dec 20, 2017
Occurred Source:
https://www.prnewswire.com/news-releases/fda-accepts-new-drug-application-for-seysara-sarecycline-for-the-treatment-of-moderate-to-severe-acne-300574162.html
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Sarecycline, Inflammatory Acne
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.